EC | HEALTHCARE

The Senior Director of Health Systems Policy serves as the Policy Team CoE’s key subject matter expert on priority pricing and reimbursement policy issues outside the US, mitigation of cost containment policies, and development of proactive policy alternatives to support patient access and Gilead’s commercial and corporate objectives. The Senior Director will support IGA leadership, Brussels-based colleagues and priority affiliates directly in a “global-to-local” model. The Senior Director will build and maintain a strong relationship with the Global Value and Access team, partnering with them on a regular basis. ...

The European Market Access & Pricing (MA&P) Director Oncology leads the development and implementation of the European Market Access strategies for Daiichi Sankyo's Oncology portfolio. The European MA&P Director Oncology will partner with pricing, HEOR/RWE, Medical Affairs & Commercial at the global, regional and country levels in order to develop winning value propositions and maximize the value of the Oncology portfolio for Daiichi-Sankyo. The job holder reports to the Head of Market Access Oncology Europe. ...

This person will lead the development of global pricing, reimbursement and access strategies for the Daiichi-Sankyo early-stage oncology assets, including both solid tumor & hematology assets and will be working cross-functionally with global, regional and country teams, including Pricing, Reimbursement and Access (PRA), Clinical development, HEOR, forecasting, pricing analytics, marketing and medical affairs. He/she will be working with the New Product Planning team and provide the PRA assumptions for forecasting, in close collaboration with regions and key countries. ...

This position is responsible for driving the HEOR strategy for EUR/INT pipeline & asset launches through leadership of the HEOR team. The role will be accountable for setting short, medium and long-term HEOR planning across the project portfolio, at a regional and local level, focused on expanding patient access. The HEOR team is responsible for preparing strategy and HEOR materials to facilitate reimbursement and maximize pricing opportunities though effective data generation prior to launch, in collaboration with EUR/INT pricing, reimbursement and market access (PRMA), medical affairs and business units as well as ...

The Director, International Health Economics and Outcomes Research (HEOR) is responsible for the strategic development and execution of health economics and outcomes research strategies to support the launch and reimbursement of products across the therapeutic disease areas in the Alexion International & Japan region. The position is part of the global HEOR team. Through key leadership and partnership across cross-functional teams, the job holder embeds global HEOR strategy into broader disease area and clinical development strategies. ...

Global Evidence & Value Development (GEVD) is an integral component of the BioPharma Global Research & Development organization that focuses on readiness for value assessment and patient access across the product lifecycle. With leadership from the GEVD Executive Strategy Lead, the Associate Director, GEVD N&I, will support the development and execution of the global value demonstration strategy. As a member of the GEVD N&I Team, you will bring scientific expertise, good project management and communication skills. Your work is embedded in cross-functional teams, in collaboration with global, regional, and local internal stakeholders such as: Epidemiology, Medical Affairs, ...

Some opportunities happen only once in a lifetime – like a job where you have the chance to change lives. At Alexion, people living with rare and devastating diseases are our Guiding Star. The Director (DIR) is responsible for the development and execution of successful P&R strategies for Alexion’s current and pipeline products for Metabolics TA in International. Specifically, the DIR will lead efforts in assessing the P&MA opportunities for pipeline products and communicating to internal and external stakeholders the market access requirements of Int’l region for Metabolics portfolio, contributing to and shaping the overall value strategy for Metabolics indications throughout lifecycle. ...